Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...

Allie Reece has shared her cancer journey on TikTok, where she has built a supportive community of thousands of followers ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Broadway actor Bret Hanna-Shuford known for Wicked has died at 46 from T-cell lymphoma Read ahead to know more about the ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News CommentaryVANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...